Systems analysis and improvement approach to optimize the hypertension diagnosis and care cascade for PLHIV individuals (SAIA-HTN): a hybrid type III cluster randomized trial

Sarah Gimbel, Ana Olga Mocumbi, Kristjana Ásbjörnsdóttir, Joana Coutinho, Leonel Andela, Bonifacio Cebola, Heidi Craine, Jonny Crocker, Leecreesha Hicks, Sarah Holte, Rodrigues Hossieke, Edgar Itai, Carol Levin, Nelia Manaca, Filipe Murgorgo, Miguel Nhumba, James Pfeiffer, Isaias Ramiro, Keshet Ronen, Nona Sotoodehnia, Onei Uetela, Anjuli Wagner, Bryan J Weiner, Kenneth Sherr, Sarah Gimbel, Ana Olga Mocumbi, Kristjana Ásbjörnsdóttir, Joana Coutinho, Leonel Andela, Bonifacio Cebola, Heidi Craine, Jonny Crocker, Leecreesha Hicks, Sarah Holte, Rodrigues Hossieke, Edgar Itai, Carol Levin, Nelia Manaca, Filipe Murgorgo, Miguel Nhumba, James Pfeiffer, Isaias Ramiro, Keshet Ronen, Nona Sotoodehnia, Onei Uetela, Anjuli Wagner, Bryan J Weiner, Kenneth Sherr

Abstract

Background: Across sub-Saharan Africa, evidence-based clinical guidelines to screen and manage hypertension exist; however, country level application is low due to lack of service readiness, uneven health worker motivation, weak accountability of health worker performance, and poor integration of hypertension screening and management with chronic care services. The systems analysis and improvement approach (SAIA) is an evidence-based implementation strategy that combines systems engineering tools into a five-step, facility-level package to improve understanding of gaps (cascade analysis), guide identification and prioritization of low-cost workflow modifications (process mapping), and iteratively test and redesign these modifications (continuous quality improvement). As hypertension screening and management are integrated into chronic care services in sub-Saharan Africa, an opportunity exists to test whether SAIA interventions shown to be effective in improving efficiency and coverage of HIV services can be effective when applied to the non-communicable disease services that leverage the same platform. We hypothesize that SAIA-hypertension (SAIA-HTN) will be effective as an adaptable, scalable model for broad implementation.

Methods: We will deploy a hybrid type III cluster randomized trial to evaluate the impact of SAIA-HTN on hypertension management in eight intervention and eight control facilities in central Mozambique. Effectiveness outcomes include hypertension cascade flow measures (screening, diagnosis, management, control), as well as hypertension and HIV clinical outcomes among people living with HIV. Cost-effectiveness will be estimated as the incremental costs per additional patient passing through the hypertension cascade steps and the cost per additional disability-adjusted life year averted, from the payer perspective (Ministry of Health). SAIA-HTN implementation fidelity will be measured, and the Consolidated Framework for Implementation Research will guide qualitative evaluation of the implementation process in high- and low-performing facilities to identify determinants of intervention success and failure, and define core and adaptable components of the SAIA-HTN intervention. The Organizational Readiness for Implementing Change scale will measure facility-level readiness for adopting SAIA-HTN.

Discussion: SAIA packages user-friendly systems engineering tools to guide decision-making by front-line health workers to identify low-cost, contextually appropriate chronic care improvement strategies. By integrating SAIA into routine hypertension screening and management structures, this pragmatic trial is designed to test a model for national scale-up.

Trial registration: ClinicalTrials.gov NCT04088656 (registered 09/13/2019; https://ichgcp.net/clinical-trials-registry/NCT04088656).

Keywords: CFIR; Cascade analysis; Continuous quality improvement; HIV; Hypertension; Implementation science; ORIC; Process mapping; Systems analysis and improvement approach (SAIA); Systems engineering.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The systems analysis and improvement approach (SAIA)
Fig. 2
Fig. 2
Hypertension cascade analysis tool (HCAT) for people living with HIV
Fig. 3
Fig. 3
Map of the study area (Manica and Sofala Provinces, Mozambique)

References

    1. Organization WH . Global Health risks: mortality and burden of disease attributable to Selected major risks. In. Geneva: World Health Organization; 2009.
    1. Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne AP. Burden of undiagnosed hypertension in sub-saharan Africa: a systematic review and meta-analysis. Hypertension. 2015;65(2):291–298. doi: 10.1161/HYPERTENSIONAHA.114.04394.
    1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224–2260. doi: 10.1016/S0140-6736(12)61766-8.
    1. Twagirumukiza M, De Bacquer D, Kips JG, de Backer G, Stichele RV, Van Bortel LM. Current and projected prevalence of arterial hypertension in sub-Saharan Africa by sex, age and habitat: an estimate from population studies. J Hypertens. 2011;29(7):1243–1252. doi: 10.1097/HJH.0b013e328346995d.
    1. World Health Organization: Global Health Estimates 2014 summary tables: deaths by cause, age and sex by WHO region 2000-2012. In. Geneva: World Health Organization; 2014.
    1. Ministerio da Saude. In.; 2014.
    1. Jessen N, Damasceno A, Silva-Matos C, Tuzine E, Madede T, Mahoque R, Padrao P, Mbofana F, Polonia J, Lunet N. Hypertension in Mozambique: trends between 2005 and 2015. J Hypertens. 2018;36(4):779–784. doi: 10.1097/HJH.0000000000001618.
    1. Antonello VS, Antonello IC, Grossmann TK, Tovo CV, Pupo BB, Winckler Lde Q. Hypertension--an emerging cardiovascular risk factor in HIV infection. J Am Soc Hypertens. 2015;9(5):403–407. doi: 10.1016/j.jash.2015.03.008.
    1. Lloyd-Sherlock P, Ebrahim S, Grosskurth H. Is hypertension the new HIV epidemic? Int J Epidemiol. 2014;43(1):8–10. doi: 10.1093/ije/dyu019.
    1. Medina-Torne S, Ganesan A, Barahona I, Crum-Cianflone NF. Hypertension is common among HIV-infected persons, but not associated with HAART. J Int Assoc Physicians AIDS Care (Chic) 2012;11(1):20–25. doi: 10.1177/1545109711418361.
    1. Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, Prins M, Reiss P, Group AGCS Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59(12):1787–1797. doi: 10.1093/cid/ciu701.
    1. Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP, Jr, Klein DB, Towner WJ, Horberg MA, Silverberg MJ. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr. 2016;73(1):39–46. doi: 10.1097/QAI.0000000000001014.
    1. Nguyen KA, Peer N, Mills EJ, Kengne AP. Burden, determinants, and pharmacological management of hypertension in HIV-positive patients and populations: a systematic Narrative review. AIDS Rev. 2015;17(2):83–95.
    1. Magodoro IM, Esterhuizen TM, Chivese T. A cross-sectional, facility based study of comorbid non-communicable diseases among adults living with HIV infection in Zimbabwe. BMC Res Notes. 2016;9:379. doi: 10.1186/s13104-016-2187-z.
    1. Krauskopf K, Van Natta ML, Danis RP, Gangaputra S, Ackatz L, Addessi A, Federman AD, Branch AD, Meinert CL, Jabs DA, et al. Correlates of hypertension in patients with AIDS in the era of highly active antiretroviral therapy. J Int Assoc Provid AIDS Care. 2013;12(5):325–333. doi: 10.1177/2325957413491432.
    1. Xu Y, Chen X, Wang K. Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis. J Am Soc Hypertens. 2017.
    1. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, et al. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179–1193. doi: 10.1097/00002030-200305230-00010.
    1. Jin C, Ji S, Xie T, Hoxtermann S, Fuchs W, Lu X, Wu H, Cheng L, Skaletz-Rorowski A, Brockmeyer NH, et al. Severe dyslipidemia and immune activation in HIV patients with dysglycemia. HIV Clin Trials. 2016;17(5):189–196. doi: 10.1080/15284336.2016.1207297.
    1. Osegbe ID, Soriyan OO, Ogbenna AA, Okpara HC, Azinge EC. Risk factors and assessment for cardiovascular disease among HIV-positive patients attending a Nigerian tertiary hospital. Pan Afr Med J. 2016;23:206. doi: 10.11604/pamj.2016.23.206.7041.
    1. Ekoru K, Young EH, Dillon DG, Gurdasani D, Stehouwer N, Faurholt-Jepsen D, Levitt NS, Crowther NJ, Nyirenda M, Njelekela MA, et al. HIV treatment is associated with a two-fold higher probability of raised triglycerides: Pooled Analyses in 21 023 individuals in sub-Saharan Africa. Glob Health Epidemiol Genom. 2018;3.
    1. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–1533. doi: 10.1016/S0140-6736(13)61809-7.
    1. Neuhaus J, Jacobs DR, Jr, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12):1788–1795. doi: 10.1086/652749.
    1. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7(9):e44454. doi: 10.1371/journal.pone.0044454.
    1. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203. doi: 10.1371/journal.pmed.0050203.
    1. Dzudie A, Rayner B, Ojji D, Schutte AE, Twagirumukiza M, Damasceno A, Ba SA, Kane A, Kramoh E, Anzouan Kacou JB, et al. Roadmap to achieve 25% hypertension control in Africa by 2025. Glob Heart. 2018;13(1):45–59. doi: 10.1016/j.gheart.2017.06.001.
    1. Kayima J, Wanyenze RK, Katamba A, Leontsini E, Nuwaha F. Hypertension awareness, treatment and control in Africa: a systematic review. BMC Cardiovasc Disord. 2013;13:54. doi: 10.1186/1471-2261-13-54.
    1. Guwatudde D, Nankya-Mutyoba J, Kalyesubula R, Laurence C, Adebamowo C, Ajayi I, Bajunirwe F, Njelekela M, Chiwanga FS, Reid T, et al. The burden of hypertension in sub-Saharan Africa: a four-country cross sectional study. BMC Public Health. 2015;15:1211. doi: 10.1186/s12889-015-2546-z.
    1. Wagner AD, Gimbel S, Asbjornsdottir KH, Cherutich P, Coutinho J, Crocker J, Cruz E, Cuembelo F, Cumbe V, Eastment M, et al. Cascade analysis: an adaptable implementation Strategy across HIV and non-HIV Delivery platforms. J Acquir Immune Defic Syndr. 2019;82(Suppl 3):S322–S331. doi: 10.1097/QAI.0000000000002220.
    1. Baekken M, Os I, Sandvik L, Oektedalen O. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. J Hypertens. 2008;26(11):2126–2133. doi: 10.1097/HJH.0b013e32830ef5fb.
    1. Sherer R, Solomon S, Schechter M, Nachega JB, Rockstroh J, Zuniga JM. HIV provider-patient communication regarding cardiovascular risk: results from the AIDS treatment for life international survey. J Int Assoc Provid AIDS Care. 2014;13(4):342–345. doi: 10.1177/2325957414530473.
    1. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi E, Wood K, Holmberg SD, Brooks JT, Investigators H. Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Prev Chronic Dis. 2013;10:E10. doi: 10.5888/pcd10.120083.
    1. Ameh S, Klipstein-Grobusch K, Musenge E, Kahn K, Tollman S, Gomez-Olive FX. Effectiveness of an integrated approach to HIV and hypertension care in rural South Africa: controlled interrupted time-series analysis. J Acquir Immune Defic Syndr. 2017;75(4):472–479. doi: 10.1097/QAI.0000000000001437.
    1. Rabkin M, Kruk ME, El-Sadr WM. HIV, aging and continuity care: strengthening health systems to support services for noncommunicable diseases in low-income countries. AIDS. 2012;26(Suppl 1):S77–S83. doi: 10.1097/QAD.0b013e3283558430.
    1. Mussa AH, Pfeiffer J, Gloyd SS, Sherr K. Vertical funding, non-governmental organizations, and health system strengthening: perspectives of public sector health workers in Mozambique. Hum Resour Health. 2013;11:26. doi: 10.1186/1478-4491-11-26.
    1. Wagner AD, Crocker J, Liu S, Cherutich P, Gimbel S, Fernandes Q, Mugambi M, Asbjornsdottir K, Masyuko S, Wagenaar BH, et al. Making smarter decisions faster: systems engineering to improve the global public health response to HIV. Curr HIV/AIDS Rep. 2019;16(4):279–291. doi: 10.1007/s11904-019-00449-2.
    1. Gimbel S, Rustagi AS, Robinson J, Kouyate S, Coutinho J, Nduati R, Pfeiffer J, Gloyd S, Sherr K, Granato SA, et al. Evaluation of a systems analysis and improvement approach to optimize prevention of mother-to-child transmission of HIV using the consolidated framework for implementation research. J Acquir Immune Defic Syndr. 2016;72(Suppl 2):S108–S116. doi: 10.1097/QAI.0000000000001055.
    1. Rustagi AS, Gimbel S, Nduati R, Cuembelo Mde F, Wasserheit JN, Farquhar C, Gloyd S. Sherr K, with input from the SST: Implementation and operational research: impact of a systems engineering intervention on PMTCT service delivery in Cote d'Ivoire, Kenya, Mozambique: a cluster randomized trial. J Acquir Immune Defic Syndr. 2016;72(3):e68–e76. doi: 10.1097/QAI.0000000000001023.
    1. Gimbel S, Coutinho, J, Sherr K.: Get with the flow: optimizing hypertension care cascades for people living with HIV in Mozambique. In: University of Washington Center for Global Health Nursing Lecture series. Seattle, USA: University of Washington; 2019.
    1. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50(3):217–226. doi: 10.1097/MLR.0b013e3182408812.
    1. Sherr K, Asbjornsdottir K, Crocker J, Coutinho J, de Fatima CM, Tavede E, Manaca N, Ronen K, Murgorgo F, Barnabas R, et al. Scaling-up the systems analysis and improvement approach for prevention of mother-to-child hiv transmission in Mozambique (SAIA-SCALE): a stepped-wedge cluster randomized trial. Implement Sci. 2019;14(1):41. doi: 10.1186/s13012-019-0889-z.
    1. Sherr K, Gimbel S, Rustagi A, Nduati R, Cuembelo F, Farquhar C, Wasserheit J, Gloyd S. With input from the SST: Systems analysis and improvement to optimize pMTCT (SAIA): a cluster randomized trial. Implement Sci. 2014;9:55. doi: 10.1186/1748-5908-9-55.
    1. Colligan L, Anderson JE, Potts HW, Berman J. Does the process map influence the outcome of quality improvement work?A comparison of a sequential flow diagram and a hierarchical task analysis diagram. BMC Health Serv Res. 2010;10:7. doi: 10.1186/1472-6963-10-7.
    1. Wiltsey Stirman S, Baumann AA, Miller CJ. The FRAME: an expanded framework for reporting adaptations and modifications to evidence-based interventions. Implement Sci. 2019;14(1):58. doi: 10.1186/s13012-019-0898-y.
    1. Ministry of Health: National HIV/AIDS prevalence, behavioral risk and information survey (INSIDA). In. Maputo, Mozambique; 2009.
    1. Sherr K, Cuembelo F, Michel C, Gimbel S, Micek M, Kariaganis M, Pio A, Manuel JL, Pfeiffer J, Gloyd S: Strengthening integrated primary health care in Sofala, Mozambique. BMC Health Serv Res 2013, 13 Suppl 2:S4.
    1. Ministerio da Saude . Relatorio Anual 2017 HIV. In. Ministerio da Saude: Maputo, Mocambique; 2014.
    1. UNAIDS: Country fact sheets Mozambique 2016 - HIV/AIDS. . In.; 2016.
    1. World Bank: Data Mozambique. In.; 2018.
    1. Moulton LH. Covariate-based constrained randomization of group-randomized trials. Clin Trials. 2004;1(3):297–305. doi: 10.1191/1740774504cn024oa.
    1. Weiner BJ. A theory of organizational readiness for change. Implement Sci. 2009;4:67. doi: 10.1186/1748-5908-4-67.
    1. Shea CM, Jacobs SR, Esserman DA, Bruce K, Weiner BJ. Organizational readiness for implementing change: a psychometric assessment of a new measure. Implement Sci. 2014;9:7. doi: 10.1186/1748-5908-9-7.
    1. Statistics H, Systems I. Service availability and readiness assessment (SARA): an annual monitoring system for service delivery, Version 2.2. In. Geneva: World Health Organization; 2015.
    1. McHugh M, Harvey JB, Kang R, Shi Y, Scanlon DP. Measuring the dose of quality improvement initiatives. Med Care Res Rev. 2016;73(2):227–246. doi: 10.1177/1077558715603567.
    1. O'Neill SM. How do quality improvement interventions succeed? Archetypes of success and failure. RAND: Santa Monica, CA; 2011.
    1. Rustagi AS, Gimbel S, Nduati R, Cuembelo MdF, Wasserheit JN, Farquhar C, Gloyd S, Sherr K: Health facility factors and quality of services to prevent mother-to-child HIV transmission in Côte d’Ivoire, Kenya, and Mozambique. Int J STD AIDS, 0(0):0956462416668766.
    1. Wagenaar BH, Gimbel S, Hoek R, Pfeiffer J, Michel C, Manuel JL, Cuembelo F, Quembo T, Afonso P, Gloyd S, et al. Stock-outs of essential health products in Mozambique - longitudinal analyses from 2011 to 2013. Trop Med Int Health. 2014;19(7):791–801. doi: 10.1111/tmi.12314.
    1. Krueger R, Casey MA. Focus groups: a practical guide for applied research: SAGE Publications. 2000.
    1. Taylor MJ, McNicholas C, Nicolay C, Darzi A, Bell D, Reed JE. Systematic review of the application of the plan-do-study-act method to improve quality in healthcare. BMJ Qual Saf. 2014;23(4):290–298. doi: 10.1136/bmjqs-2013-001862.
    1. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50. doi: 10.1186/1748-5908-4-50.
    1. Choosing Interventions that are Cost-Effective. Estimates of Unit Costs of Patient Services [].
    1. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–2223. doi: 10.1016/S0140-6736(12)61689-4.
    1. Commission on Macroeconomics and Health: Macroeconomics and health: investing in health for economic development. In. Boston: Center for International Development at Harvard University 2001.
    1. Galárraga Omar, Colchero M Arantxa, Wamai Richard G, Bertozzi Stefano M. HIV prevention cost-effectiveness: a systematic review. BMC Public Health. 2009;9(Suppl 1):S5. doi: 10.1186/1471-2458-9-S1-S5.
    1. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–124. doi: 10.2471/BLT.14.138206.
    1. Nugent R, Barnabas RV, Golovaty I, Osetinsky B, Roberts DA, Bisson C, Courtney L, Patel P, Yonga G, Watkins D. Costs and cost-effectiveness of HIV/noncommunicable disease integration in Africa: from theory to practice. AIDS. 2018;32(Suppl 1):S83–S92. doi: 10.1097/QAD.0000000000001884.
    1. Drummond MF, Jefferson TO Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275–283. doi: 10.1136/bmj.313.7052.275.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi